Studies have shown that DOACs are effective in preventing and treating VTE in cancer patients. Recent clinical trials, such as the Hokusai VTE Cancer Study and the SELECT-D trial, have demonstrated that DOACs are at least as effective as low molecular weight heparins (LMWH) in preventing recurrent VTE, with a comparable safety profile.
